Search Results 271-280 of 15109 for TNF
Disseminated histoplasmosis and hemophagocytic lymphohistiocytosis in a patient receiving TNF-alpha inhibitor therapy. IDCases. 2022; 29:e01603. Epub 2022 ...
anti-TNF alpha agents) =< 2 weeks prior to randomization, or anticipation of need for systemic immunosuppressive medication during study treatment, with the ...
... Tumor Necrosis Factor ... 2012 Mar; 18: (2)92-5. View PubMed; Raja H, Matteson EL, Michet CJ, Smith JR, Pulido JS. Safety of Tumor Necrosis Factor Inhibitors ...
Other TNF or IL-17 blockers (such as infliximab, certolizumab pegol, secukinumab, ixekizumab, brodalumab, or their biosimilars) within 12 weeks prior to ...
Publications. Shanafelt TD, West CP, Sinsky C, Trockel M, Tutty M, Wang H, Carlasare LE, Dyrbye LN. Changes in Burnout and Satisfaction With Work-Life ...
About this study. The purpose of this study is to demonstrate feasibility of conducting a decentralized therapeutic clinical trial of triple oral metronomic ...
... TNF] factor agents) within 14 days prior to randomization or anticipation of need for systemic immunosuppressive medications during the study. Note ...
methotrexate, azathioprine, anti-tumor necrosis factor (TNF) agents, etc. with the exception of steroids - Administration of a live or live attenuated ...
... (TNF- a) inhibitors. * Medications that are under investigation for the treatment of IPF including inhaled treprostinil and Phosphodiesterase-4 (PDE-4) ...
... TNF agents, and rituximab). Subjects with an MMT-8 score ≤ 66 (see Appendix B) must also have at least 2 other core set measures meeting the criteria ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your donation powers the future of medicine and helps save lives.